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Title: Treatment escalation for children with exacerbations of asthma – what works? 
An overview of Cochrane Reviews. 
Implications for practice and research: 
• The authors acknowledge a lack of comparative studies regarding treatment 
options therefore recommendations to change practice should be applied with 
caution. Intravenous magnesium sulphate appears to reduce length of 
inpatient stay.  
• No evidence that any treatments reduce risk of intensive care admission. 
• Need to develop internationally agreed outcome measures for future trials. 
• Need multi-centred trials on second-line therapies with separate focus on pre-
school children with wheeze. 
Context 
Exacerbation of asthma is one of the most common reasons for children to attend an 
emergency department. Children generally respond well to first line treatments such 
as inhaled short-acting beta-agonists and systemic corticosteroids. For the minority 
requiring second line therapies the availability of numerous interventions has led to 
inconsistency in management. This overview of Cochrane reviews has sought to 
identify high certainty evidence from existing reviews regarding current interventions.  
Methods 
The primary outcome of the review1 was to identify efficacy and safety of second line 
therapies for children with acute exacerbation of asthma. The relatively new 
approach of systematically reviewing systematic reviews, known as an overview or 
umbrella review was used2. Secondary outcomes focused on gaps in evidence for 
future research and to identify outcome measures/scores. Data collected from the 
Cochrane database included randomised and non-randomised clinical trials covering 
all types of comparison studies such as drug vs placebo with identified primary and 
secondary outcomes. GRADE3 (Grading of Recommendations, Assessment, 
Development and Evaluations) was used to measure the quality of the data, while 
ROBIS (risk of bias in systematic reviews) assessed it for bias. 
Findings 
From the 13 systematic reviews included the findings were grouped into one of the 
three interventions identified: inhaled bronchodilators, parenteral bronchodilators, 
and interventions to reduce the work of breathing. Although there was low certainty 
evidence of the use of inhaled bronchodilators regarding admission to hospital or 
intensive care, there was moderate-certainty evidence that adding inhaled 
anticholinergic agents with the inhaled beta2-agonists did reduce risk of hospital 
admission. There was high certainty evidence that intravenous magnesium sulphate 
reduced the length of stay in hospital and could also reduce admission to hospital. 
However, the evidence for using inhaled Heliox to assist in respiratory effort and 
reduce risk of admission to hospital was of low certainty.  
Commentary 
Systematic reviews are valued for the high-quality evidence they produce however 
the increasing number of published reviews makes it difficult for healthcare staff to 
keep up to date5. Overviews such as this support clinical decision making and 
guideline development2.Managing acute exacerbations of asthma in children is 
challenging; the increasing number of treatments available and the variation in 
approaches across departments and countries challenges us further. The high 
certainty evidence from this review1 supporting the use of intravenous (IV) 
magnesium sulphate in reducing length of stay for children is reassuring. However, 
the high certainty evidence supporting IV magnesium sulphate as a means of 
avoiding admission is at odds with established guidance. British Thoracic 
Society/SIGN6 guidance recommend its use where first line inhaled therapy has 
failed, indicating a child in the moderate to severe category. This group of children 
would be admitted for ongoing treatment and not discharged directly from an 
emergency department.   
This review1 is helpful for those developing local and national guidelines as it will 
strengthen current practice regarding the use of intravenous magnesium sulphate. 
For the healthcare professional assessing and treating a child with acute 
exacerbation of asthma, recognising that the evidence base for much of the current 
interventions is unclear or of low certainty is not reassuring. However, it should be 
recognised that this reflects a lack of quality research rather than a lack of safe and 
effective treatments.   
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